Introduction. Advanced and metastatic basal cell carcinomas (BCCs) are rare but still
Introduction
Basal cell carcinoma (BCC) is a skin cancer, considered to originate in the hair follicle. It is the most commonly diagnosed skin cancer and, except for actinic keratosis, the most frequently diagnosed human tumor.
Most BCCs are solitary 1 and, in respect of size, histologic subtype, number and patient characteristics, can be treated with surgery, cryo-, photodynamic or radiotherapy, or using 83.4% (95% CI 74.7-85.9) of imiquimod patients were tumor-free 2 . At three year follow up, the results dropped to 58% (95% CI 47.8 -66.9) in MAL-PDT, to 68.2% of fluoruracil (95% CI 58.1-76.3) and remained stable in imiquimod group, with 79.7% (95% CI 71.6-85.7) of patients remaining tumor-free 3 . Superficial radiotherapy (RT), a treatment option which can be recommended for elderly patients or patients with large facial lesions, showed estimated 5-year recurrence rate of 15.8% in a retrospective setting 4 . These treatment options, although most commonly used for treatment of BCCs, are however inappropriate for treatment of advanced disease. Anatomical location, dimension and morbidity of surgery, makes management of advanced BCCs a real challenge for clinicians.
Defining advanced basal cell carcinoma
The majority of BCCs are easily cured by surgery. However, a small subset of BCCs are not amenable to either surgery or radiotherapy, thus posing a challenge for clinical management.
Complex cases include locally advanced (laBCC) and metastatic BCC (mBCC). As locally advanced BCC is rare and rather heterogeneous, there is no officially recognized definition of the term. Other terms used in the literature include "severe", "advanced" and "aggressive" BCC 5 . Advanced BCC sometimes comprises laBCC and mBCC.
A recent analysis of 2938 BCC cases in a Swiss tertiary reference center classified 0.6% of cases as severe with the potential to benefit from Smoothened (SMO) inhibitor therapy.
Severe cases were defined as follows: 10 or more diagnoses of BCCs during 5 investigated years, severe clinical progress (including serious complications, BCCs inappropriate for surgery, metastatic BCC) or indication for extensive treatment (including need for resection of noncutaneous structures, surgery combined with irradiation and any systemic treatment) 6 .
As there is no standard definition of laBCC, a multidisciplinary panel from the UK defined LaBCC and mBCC are a complex and heterogeneous disease and should be treated in a specialized treatment center with an interdisciplinary tumorboard to discuss the best suited, individualized treatment for each patient.
Pathogenesis
Most, if not all, BCCs demonstrate genetic alterations in genes involved in the Hedgehog (Hh) signalling pathway, resulting in a stem cell like state without terminal keratinocyte differentiation and augmenting BCC's proliferation 12 . The most common alteration is loss of function of patched homologue 1 (PTCH1), which typically inhibits the signalling activity of SMO in the cilium 13 . Gorlin's syndrome is an autosomal-dominant disease, presenting with a variety of developmental disorders and neoplasias, especially BCCs at younger age.
Molecular analysis of patients with the syndrome revealed mutations in PTCH1 gene located on chromosome 9q22 [14] [15] [16] . Since PTCH1 inhibits Hh signalling pathway, inactivating mutations in PTCH1 lead, through loss of inhibition, to pathway up-regulation and development of a BCC from the stem cells of the hair follicle tissue 17, 18 .
Although mutations in PTCH1 are causative for the Gorlin's syndrome and can be identified in majority of the patients, some individuals lack alterations in the gene. Exome sequencing of germline DNA was performed in four unrelated PTCH1-negative individuals from families with Gorlin's syndrome. In three of them, alterations in Suppressor of fused (SUFU) gene were identified 19 . SUFU gene, another factor affecting the Hh signalling pathway, encodes a protein, which negatively regulates the Hh pathway by binding and sequestering glioma associated oncogene (GLI) transcription factors in the cytoplasm 20 . In mammals GLI transcription factors exist in three isoforms, namely GLI1, GLI2 and GLI3, and SUFU binds all 21 , thus withholding translocation to the nucleus and induction of expression of cellular differentiation, proliferation and survival regulating genes 20, 22 . Moreover, a case of medulloblastoma, malignancy known to be associated, but rare in Gorlin's syndrome, was documented in all three families with SUFU mutation 19 .
Introduction to the compound
The development of SMO inhibitors was based on the observation that cyclopamine, a substance found in the corn lily, can suppress the Hh pathway and result in birth defects (cyclopia) of sheep 23 . Today, several molecules are in clinical development 24 , vismodegib and sonidegib being the most advanced ones that are established treatment options for patients with laBCC, mBCC or Gorlin's syndrome (Table 1) 25 .
Chemistry
, is selective inhibitor of SMO. It is structurally unrelated to cyclopamine.
Pharmacokinetics and Pharmacodynamics
Sonidegib had shown high tissue penetration and bioavailability in the preclinical studies 26 .
The data collected during Phase I study, demonstrated that median time to maximal plasma concentration (T max ) after oral administration is 2 hours (1-48h). Plasma exposure (maximum of serum concentration (C max ) and area under the curve (AUC)) after a single 100 to 400 mg dose increases dose-proportionally, for doses above 400 mg the increase is less doseproportional 27 .
A relatively long half-life of 29.6 days 28 might be the consequence of tight tissue and/or plasma protein binding 27 . Sonidegib is a lipophilic drug, whose bioavailability increased fivefold when taken with high-fat food. It is metabolised in the liver, mostly by cytochrome P450
(CYP) 3A4 and excreted mainly with faeces and urine 28, 29 .
Clinical efficacy

Phase I studies
The phase I study was accompanied by translational research that demonstrated a dosedependent reduction in GLI1 mRNA expression 27 . The maximal tolerated dose (MTD) was 800 mg once daily or 250 mg twice daily. Below the MTD, sonidegib was tolerated well with several low grade (grade 1-2) class related adverse events (AE 
Pivotal Phase II study
BOLT is a multicenter, randomized, double-blind, phase II trial (NCT01327053), conducted to evaluate efficacy and safety of sonidegib. In this study, patients with laBCC and mBCC were randomized in a 1:2 fashion to be treated with sonidegib 200 mg (n = 79; laBCC, n = 66; mBCC, n = 13) or 800 mg (n = 151; laBCC, n = 128; mBCC, n = 23) daily. Patients with laBCC were further stratified in respect to having aggressive (micronodular, infiltrative, multifocal, basosquamous or sclerosing) and non-aggressive (superficial and nodular) histological subtypes of BCC 30 . Primary endpoint of the study was objective response rate (ORR), described as confirmed partial response (PR) or confirmed complete response (CR). 
Efficacy in patients with Gorlin's syndrome
Efficacy of sonidegib in Gorlin's patients was observed in 2 randomized double-blind studies.
In the NCT01350115 trial, 7 patients received 400 mg sonidegib QD and were compared to 2 patients in placebo arm. At week 16, response was clearly better in sonidegib arm with complete histological clearance of main target lesion being 43% compared to 0% in placebo arm. In BOLT trial, 8 patients have reached CR in 800 mg arm (n=13) and none in the 200 mg arm (n=3), nevertheless no treated patients showed progressive disease. AEs' rate (88%) was similar to that observed in patients with sporadic BCCs 33 . These results advocate the using SMO inhibitors not only for treatment but also for cancer chemoprevention.
Long term outcomes and resistance
Long term data including the key information of cure rates for Hh inhibitors are still limited, the optimal treatment duration is not yet defined and there are already documented cases with acquired resistance to SMO inhibitors' therapy.
Two groups of scientists 34, 35 analyzed vismodegib resistant BCCs and identified, that majority of the relapsed tumors (85%) harbored genetic alterations downstream of PTCH1, most commonly in SMO (50% 34 and 65% 35 ), and concurrent copy number changes in SUFU and GLI2, all of which lead to reactivation of the Hh pathway. The SMO mutations were absent in untreated Gorlin and rare (15%) in sporadic BCCs. Four of them, namely SMO-T241M, SMO-I408V, SMO-A459V, and SMO-C469Y, were not detected in the cohort of untreated BCCs, strongly suggesting they could be key drivers in resistance 35 . Moreover,
Atwood et al. identified, that in presence of vismodegib, SMO mutant cells had growth
advantage when compared to SMO wild-type tumor cells 34 .
Treatment response to sonidegib in patients, with laBCC, resistant to vismodegib, was evaluated in an open label investigator initiated study. Of 9 patients, who were resistant to vismodegib, all were treated with sonidegib and 5 experienced disease progression, three experienced stable disease, in one case response was not evaluable 36 . This, in addition to detection of intra-tumor heterogeneity of resistance mechanisms, suggests that other approaches (itraconazole, arsenic trioxide, IFN α-2b) or new SMO inhibitors (LEQ 506, XL139, Taladegib, TAK-441) could be needed to overcome resistance 24, 35 .
Safety and tolerability
At least one adverse event was experienced by almost all patients in both 200 mg (97,5%) and 800 mg (100%) treatment arms 31 , yet 200 mg dose showed more favorable safety profile than 800 mg dose, with less grade 3-4 AEs (43% vs 64%) and AEs leading to dose reduction (32% vs 60%) or treatment discontinuation (22% vs 36%) [30] [31] [32] . Most common grade 3-4 AE, increased CPK, was also more frequently observed in 800 mg population (13.3% vs 6.3% in 200 mg). Most common serious AEs, rhabdomyolysis (1.3% vs 3.3%) and increased CPK (1.3% vs 2.7%) were reported by investigators, but none of rhabdomyolysis cases were confirmed by the committee of experts 32 . AEs were the main reason of treatment discontinuation (25.3% in 200 mg and 34.4% in 800 mg treatment arms), in 59% of cases grade 1 or 2 AEs being the cause 32 . A total of 8 in treatment deaths were documented (n=1 in 200 mg and n=7 in 800 mg arms) at 30 month analysis, all reportedly unrelated to the sonidegib treatment 31 . 13 . After additional 12 months of follow-up, OR of vismodegib receiving patients improved to 47,6% in laBCC arm and to 33,3% in mBCC arm 37 .
Comparison between the Hh inhibitors
Similar to sonidegib, most common were class specific toxicities, such as muscle spasms, dysgeusia, alopecia, fatigue and weight loss with all vismodegib receiving patients experiencing at least one, mostly mild, AE. At the time of primary analysis, rate of severe AEs of grade 3 or 4 (most commonly muscle spasms, fatigue, loss of appetite and weight loss) was 31,7% 13 . After additional 12 months of follow up, it increased to 51,9% 37 and was greater than that, observed in patients receiving the approved dosis of sonidegib 32 . As mentioned above, sonidegib was ineffective in patients with advanced BCC, resistant to vismodegib, suggesting that both drugs present comparable class effects.
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Conclusion
The activity of sonidegib in patients with locally advanced and metastatic basal cell carcinoma is good and comparable to vismodegib. The drug seems to be more effective in patients with locally advanced rather than metastatic BCC, has advantage of oral administration, but shows quite high rate of adverse events mostly grade 1 and 2. Results from studies with patients with Gorlin's syndrome illustrate the potential of using of sonidegib not only for treatment but also for cancer chemoprevention. The 200 mg daily dose demonstrates a reasonable benefit/ risk ratio, but since there are no comparative clinical trials, it is not appropriate to make direct comparison to the competitor vismodegib.
Expert opinion
BCC is model tumor for a Hh driven malignancy. Most BCC do not metastasize and are curable by conventional treatment approaches. Therefore, the few cases of metastatic BCC open oppurtunities for research. It would be important to understand the key drivers of metastatic disease. There is a good chance that these pathways are discovered in BCCs.
Locally advanced BCCS are not curable by surgery and therefore present a paradigm for the development of Hh inhibitors. In order to investigate the molecular processes involved in tumor regression which might help to improve the therapy outcome, repeated biopsies can be used to monitor the detailed molecular cascades involved. With a superficial large tumor as typically seen in laBCC, this should be feasible. Unfortunately, there was no clear strategy covering this issue in the vismodegib trials. During the BOLT trial biopsies were collected systematically and used for the analysis of GLI expression. However, there is a plethora of other issues that need investigation. Remaining tumor material form clinical trials still remain with the sponsoring companies. These tissues should be offered to research groups acting in the field. We have been able to collect biopsies in only a few patients. Nevertheless, we found profound alterations in the morphology with an increased keratinization and substantial changes in the microenvironment facilitating local immune responses 42 .
In our opinion, early biopsies (within 5 days after treatment initiation) might open additional perspectives on the mode of action.
The final goal for the treatment of BCCs might be a reasonable long term disease control or cure in at least 50% of the patients which implies a series of additional well designed trials.
Reviewing the recruitment rates of BOLT and Stevie, these trials are feasible.
Possible treatment combinations have been discussed earlier 24 . However, based on the impact of Hh inhibition on the immune privilege of BCC, combinations with immunostimulants such as interferon, imiquimod or checkpoint inhibitors appear promising and realistic also in the context of the known adverse reaction profiles. 
